Celldex Therapeutics, Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Financial statements are unaudited; amounts below are in millions unless stated otherwise.
Business context
Celldex is a clinical-stage biopharmaceutical company developing immunotherapies and antibody-drug conjugates. Its lead programs included rindopepimut for glioblastoma (Phase 3 and Phase 2), CDX-011 for advanced breast cancer (Phase 2b), and CDX-1127 (Phase 1). Rotarix royalties were its principal reported revenue source.
Key financial metrics
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Total revenue | $2.009 | $1.952 | $4.442 | $4.468 |
| Research and development expense | $11.114 | $7.169 | $21.881 | $14.021 |
| Operating loss | $(13.488) | $(9.881) | $(26.776) | $(19.538) |
| Net loss | $(13.773) | $(10.236) | $(27.289) | $(20.295) |
| Basic and diluted loss per share | $(0.23) | $(0.27) | $(0.50) | $(0.58) |
For the six months ended June 30, 2012, operating cash use was $25.512 million, investing cash use was $18.430 million, and financing provided $50.605 million. Cash and cash equivalents ended the period at $18.563 million; marketable securities were $60.109 million. Working capital was $67.8 million. Total assets were $122.129 million, total liabilities $27.581 million, and stockholders’ equity $94.548 million.
Term-loan carrying balance was approximately $13.9 million, including $5.294 million current and $8.608 million long-term. The loan bears interest at no less than 9.50%; maturity was extended to December 2014, with principal installments beginning April 2012. No additional advances are available. The company reported compliance with the loan covenants.
No meaningful positive operating margin was reported: the company recorded an operating loss, while royalty revenue was matched by royalty expense. The filing does not provide a conventional gross-margin measure.
Changes versus the prior comparable period
- Q2 revenue rose 3%, but six-month revenue fell 1%. Product royalties declined 4% in Q2 and 5% for the six-month period; the company attributed the decrease to Rotarix royalties retained after the PRF arrangement and payable to Cincinnati Children’s Hospital.
- R&D expense increased 55% in Q2 and 56% for the six months. Higher clinical-trial and product-development costs—particularly for rindopepimut’s ACT IV and ReACT studies—were the main drivers.
- Six-month net loss widened by $6.994 million, principally because of higher R&D spending. Loss per share was lower than the prior year despite the larger net loss, alongside a higher weighted-average share count.
- The company raised $51.9 million net from common-stock sales in the first half, including a $43.4 million public offering and $8.5 million through its controlled equity offering. Shares outstanding increased to 58.754 million from 44.211 million at year-end 2011.
Outlook, commentary and risks
- Management believed available cash, cash equivalents and marketable securities would fund estimated working capital needs and planned operations for at least the next 12 months. It also said additional capital may be needed for longer-term liquidity; financing availability and acceptable terms are not assured, and equity financing could dilute shareholders.
- Management expected operating cash use and product-development expense to rise over the next 12 months, primarily due to rindopepimut clinical development. It estimated ACT IV would cost more than $50 million to complete.
- In January 2012, FDA placed the CDX-011 Phase 2b study on partial clinical hold after GMP violations were found at a contract manufacturer. No new patients could start CDX-011 treatment, although certain existing or crossover patients could continue using the affected lot under specified conditions. Reprocessing remaining vials required FDA review; failure to reprocess or obtain approval could delay a subsequent trial.
- Management expected updated ACT III rindopepimut survival data and mature EMERGE CDX-011 data in Q4 2012, preliminary ReACT data in mid-2013, and planned to start a CDX-1135 Phase 2 pilot in the second half of 2012.
- Rotarix royalties were subject to agreements scheduled to end in December 2012; the company did not expect the PRF return threshold to be reached by then. This creates uncertainty around future royalty economics.
- Key risks include clinical safety and efficacy, trial duration and cost, regulatory approval, manufacturing and clinical-supply availability, competition, intellectual-property exposure, and the ability to secure funding and partners. No material changes to previously disclosed risk factors were reported. The company reported no legal proceedings and effective disclosure controls.
Important facts for investors to verify
- Cash runway assumptions against the projected rise in clinical-trial spending and management’s 12-month funding estimate.
- ACT IV progress, total cost and enrollment; anticipated ACT III survival results; and EMERGE’s mature efficacy and safety data.
- FDA disposition of CDX-011 reprocessing and the timing and requirements for any follow-on trial.
- Post-December 2012 Rotarix royalty receipts and the implications of the PRF agreement’s scheduled termination.
- Potential future capital needs, dilution and loan repayment obligations, including fees, covenants and the December 2014 maturity.